v3.26.1
EQUITY
 6 Months Ended
Jun. 30, 2026
Equity [Abstract]  
EQUITY

NOTE 6 - EQUITY:

 

  a. Authorized Capital Stock
     
    As of June 30, 2026, the Company had 255,000,000 authorized shares of capital stock, par value $0.0001 per share, of which 250,000,000 are shares of common stock and 5,000,000 are shares of “blank check” preferred stock.
     
  b. Preferred Stock
     
   

As of June 30, 2026, there were 1,718 shares of Series C preferred stock outstanding, convertible into an aggregate of 7,952 shares of the Company’s common stock, with a total stated value of $10,997.

     
  c. Pre-Funded Warrants
     
    As of June 30, 2026, there are 43,092,107 outstanding pre-funded warrants.

 

 

  d. Warrants
     
    As of June 30, 2026, the Company has outstanding warrants to purchase an aggregate of 25,828,164 shares of common stock as follows:

 

   Number of
underlying
Common stock		   Exercise price   Expiration date
Series J Warrants   12,914,086    1.3827   *
Series K Warrants   12,914,078    1.3827   *
Total Warrants   25,828,164         

 

  *

The Series J Warrants and Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) (A) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 cm and (B) in the case of the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of CGuard Prime in the U.S. begins. Following the commencement of the first commercial sales of CGuard Prime in the United States, which occurred during the third fiscal quarter of 2025 in July 2025, the Series K Warrants are scheduled to expire twenty (20) trading days after the end of the fourth fiscal quarter thereafter, which is October 28, 2026. 

 

    During the six months ended June 30, 2026, a total of 1,092,344 Series G warrants expired unexercised.

 

  e. Share-Based Compensation
     
    During the six months ended June 30, 2026, the Company granted 3,725,216 restricted shares of the Company’s common stock to employees and directors. The shares granted to employees are subject to a three-year vesting period, with one-third of such awards vesting each year, subject to continued service. The shares granted to directors are subject to a one-year vesting period, subject to continued service.
     
    The fair value of the above restricted shares was approximately $5.8 million.
     
   

During the six months ended June 30, 2026, the Company granted 1,114,792 restricted stock units convertible into shares of the Company’s common stock to the Company’s chief executive officer. The restricted stock units are subject to a three-year vesting period, with one-third of such awards vesting each year, subject to continued service.

     
    The fair value of the above restricted stock units was approximately $1.8 million